ROLLER COASTER FOR THE PIONEERS OF IMMUNO-ONCOLOGY
April 24, 2026
"Let us agree, however, to the company’s and investors’ credit that until now all the indicators were green for efti…"
April was particularly eventful for Immutep, illustrating the high volatility that now characterizes the immuno-oncology sector. The company saw its share price plunge sharply, losing nearly 80% of its value following a recommendation from the independent data monitoring committee (IDMC) to halt the phase III TACTI-004 trial for futility, based on efficacy and/or safety data deemed insufficient.
This trial represented a major strategic milestone, targeting marketing approval in the first-line setting for advanced or metastatic non-small cell lung cancer in...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.
Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.
RELATED ARTICLES
RECORD IPO FOR KAILERA THERAPEUTICS
$625 million! That is the amount Kailera Therapeutics raised in its IPO on an euphoric NASDAQ. An amount that surprised not only thecompany, but also
CHANGING THE HISTORY OF CYSTIC FIBROSIS
To develop its five cystic fibrosis treatments, Vertex conducted approximately 200 adult and pediatric clinical trials in more than 24 countries and 5
A CANINE VACCINE THANKS TO CHATGPT?
The news had all the hallmarks of a hoax or a fake news story spread on social media: an Australian data engineer had supposedly treated and saved his